The mention of naltrexone caught my eye:
Contrave, which is being developed with Takeda Pharmaceutical Co. (TKPYY, 4502.TO), is a combination of two drugs already on the market, addiction-treating naltrexone and the antidepressant bupropion, commonly known by the brand name Wellbutrin. Orexigen argued that Contrave's ingredients have been on the market for 20 years and haven't shown major cardiovascular-safety problems.
Interesting, don't you think?
I heard one doctor ascribed the ability of Contrave to reduce weight to the fact that naltrexone boosts metabolism. Now I wonder if naltrexone, by boosting the metabolism and burning more glucose, thereby reducing insulin, has its positive effect on MS. In the same manner, exercise would have its positive effect also.